Sunil Patel
No más puestos en curso
Perfil
Sunil Patel worked as a Director at Ligand Pharmaceuticals, Inc. and as an Independent Director at OmniAb Operations, Inc. He was also a Principal at Gilead Sciences, Inc., ProCyte Corp., and Abgenix, Inc. He held the position of Vice President-Corporate Development at Allos Therapeutics, Inc. and Vice President-Corporate Development & Marketing at BiPar Sciences, Inc. He was the CFO, Executive VP-Corporate Development & Finance at OncoMed Pharmaceuticals, Inc. from 2017 to 2018.
Mr. Patel was a Researcher at ZymoGenetics, Inc. and held the position of Principal at Connetics Corp.
He was also a Principal at McKinsey & Co., Inc. from 1998 to 2003.
Mr. Patel received his undergraduate degree from the University of California, Berkeley and his graduate degree from the University of Washington.
Antiguos cargos conocidos de Sunil Patel.
| Empresas | Cargo | Fin |
|---|---|---|
OmniAb Operations, Inc.
 OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Director/Board Member | 01/08/2023 |
| OMNIAB, INC. | Director/Board Member | 01/08/2023 |
| ONCOMED PHARMACEUTICALS INC | Director of Finance/CFO | 09/03/2018 |
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Sales & Marketing | - |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | - |
Formación de Sunil Patel.
| University of Washington | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| OMNIAB, INC. | Commercial Services |
| Empresas privadas | 9 |
|---|---|
ProCyte Corp.
 ProCyte Corp. Pharmaceuticals: MajorHealth Technology ProCyte Corp. manufactures & markets products for tissue repair, skin health & hair care. It develops products that promote healthy skin, tissue repair and help for thinning hair. It markets the products to cosmetic surgeons and dermatologists through its direct sales force and through distributors for the International markets. The company was founded in 1986 and is located in Redmond, WA. | Health Technology |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Sunil Patel
